Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363775 | 0.77 | AR (0.44) | SLC22A12EPAS1AR | |
| SCHEMBL2520409 | 0.74 | SLC22A12 (0.40) | SLC22A12EPAS1AR | |
| SCHEMBL15057108 | 0.73 | EPAS1 (0.35) | EPAS1 | |
| SCHEMBL4443907 | 0.72 | SLC22A12 (0.40) | SLC22A12AR | |
| SCHEMBL13303936 | 0.72 | — | — | |
| SCHEMBL5728291 | 0.72 | EPAS1 (0.45) | SLC22A12EPAS1 | |
| SCHEMBL18981852 | 0.72 | EPAS1 (0.36) | EPAS1 | |
| SCHEMBL3958603 | 0.71 | EPAS1 (0.41) | SLC22A12PGREPAS1AR | |
| SCHEMBL2259279 | 0.71 | AR (0.44) | SLC22A12EPAS1ARPLA2G7 | |
| SCHEMBL2522713 | 0.71 | SLC22A12 (0.41) | SLC22A12PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370438-A1 | IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | Exelixis, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | SLC22A12 3246/4885PGR 1194/4885EPAS1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.